This Week’s Biopharma News: Amgen Deepens US Manufacturing Push - Takeaways - MDSpire
Feature

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min

Share

  • 1

    Pfizer’s ELREXFIO improves PFS in multiple myeloma.

  • 2

    Positive topline results for Viridian's elegrobart in chronic thyroid eye disease.

  • 3

    JNJ-4804 shows promise in refractory inflammatory bowel disease.

  • 4

    Positive data for abdakibart in hidradenitis suppurativa.

  • 5

    FDA approves daraxonrasib expanded access for metastatic pancreatic cancer.

  • 6

    NIKTIMVO approved in Australia for chronic graft-versus-host disease.

Original Source(s)

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

  • May 12, 2026

Related Content

Roswell Park Study: Inhibiting Regulator Protein Can Make Aggressive Prostate Cancers More Vulnerable

Team shows BCL-2 promotes treatment resistance, uncovering strategy for making tumors respond to treatment.

  • by

  • May 11, 2026

  • 4 min
New Research Sheds Light on How Precancerous Lesions Form in the Pancreas

Discoveries about two metabolic enzymes could point the way to biomarkers, opportunities to prevent cancer.

  • by

  • May 11, 2026

  • 3 min
Roswell Park Experts Highlight Untapped Potential of CDK Inhibitor Cancer Therapy

Worldwide, more than a million breast cancer patients have been treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which slow or stop the uncontrolled multiplication of cancer cells.

  • by

  • May 11, 2026

  • 3 min